RDEA3170 Tablet and Capsule Bioavailability Study

Inclusion Criteria: * Subject is able to understand the study procedures and the risks involved, and is willing to provide written informed consent before the first study-related activity. * Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2. * Subject has a Screening serum urate level of 4 to 7 mg/dL. * Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment. Exclusion Criteria: * Subject has a history or suspicion of kidney stones. * Subject has undergone major surgery within 3 months prior to Screening. * Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1. * Subject has clinically unacceptable physical examination, per the Investigator's judgment. * Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment. * Subject has Screening clinical safety laboratory parameters (serum chemistry \[other than serum creatinine and serum urate\], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator. * Subject has a serum creatinine value above the upper limit of normal at the Screening visit. * Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment. * Subject has a history of cardiac abnormalities * Subject cannot swallow multiple tablets or capsules. * Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.